Adding a Peptide Blood Test Makes Kidney Function Estimates Far More Accurate | Research

The takeaway

Combining the peptide biomarker cystatin C with creatinine in kidney function equations significantly improves accuracy and prevents overdiagnosis of chronic kidney disease.

16.9% reclassified
Nearly 1 in 6 patients who appeared to have CKD based on creatinine alone were correctly identified as having normal kidney function when cystatin C was added

What the researchers found

Combining cystatin C (a small peptide biomarker) with creatinine to estimate kidney filtration rate (GFR) is significantly more accurate than using either marker alone. The combined equation reduced errors by about a third — only 8.5% of estimates were off by more than 30%, compared to 12.8% for creatinine alone and 14.1% for cystatin C alone (both P<0.001).

Critically, for patients in the diagnostic gray zone (estimated GFR 45–74), the combined equation correctly reclassified 16.9% of those who appeared to have chronic kidney disease back to normal kidney function — preventing unnecessary diagnoses and treatments.

Why it matters

Chronic kidney disease (CKD) diagnosis relies on estimating how well your kidneys filter blood. The standard creatinine-based test is imprecise and can falsely diagnose CKD in many patients. By adding cystatin C — a peptide freely filtered by the kidney — doctors can get a much more accurate picture of kidney function, preventing overdiagnosis and ensuring that patients who truly have CKD get identified and treated earlier.

The numbers in context

n=5,352 (development) · n=1,119 (validation) · 13 + 5 studies · Combined equation error >30%: 8.5% vs 12.8% (creatinine) vs 14.1% (cystatin C) · Net reclassification: 19.4% · 16.9% correctly reclassified as normal

How the study worked

Cross-sectional study developing and validating GFR estimation equations. Development used 5,352 participants from 13 studies; validation used 1,119 participants from 5 different studies where GFR was directly measured. Three equations were compared: creatinine-based, cystatin C-based, and combined creatinine-cystatin C. All assays were traceable to primary reference materials.

Who was studied

6,471 adults across 18 studies with diverse kidney function levels, used for development (5,352) and validation (1,119) of GFR estimation equations

What this study cannot tell us

Cross-sectional design cannot track changes in kidney function over time. The equations were developed from specific populations and may perform differently in underrepresented groups. Cystatin C levels can be affected by factors other than kidney function (inflammation, thyroid disease, corticosteroid use), which could introduce errors in certain patients.

How to read the evidence

Published in the New England Journal of Medicine, this large-scale study used data from 18 studies with over 6,400 participants and validated against directly measured GFR — the gold standard. This represents very strong diagnostic accuracy evidence.

When this study was published

Published in 2012. This is a foundational study that established the CKD-EPI creatinine-cystatin C equation now widely used in clinical practice. The equations and findings remain current and are incorporated into kidney disease guidelines.

The bigger picture

This NEJM study established the CKD-EPI creatinine-cystatin C equation that is now used worldwide. It demonstrated how a peptide biomarker can fundamentally improve clinical diagnostics. The work has influenced kidney disease guidelines globally and is an example of how understanding peptide biology — in this case, how cystatin C is freely filtered by the kidney — translates directly into better patient care.

Questions still open

Should cystatin C testing become routine for all kidney function assessments, or should it be reserved for cases where creatinine-based estimates are uncertain?
How do conditions that affect cystatin C levels independently of kidney function (like inflammation or thyroid disease) impact the accuracy of the combined equation?
Could other peptide biomarkers further improve GFR estimation when combined with creatinine and cystatin C?

Common questions

What is cystatin C and why is it useful for kidney testing?

Cystatin C is a small protein (peptide) produced by all cells in your body at a constant rate. Unlike creatinine, which is affected by muscle mass, diet, and other factors, cystatin C is freely filtered by the kidneys and provides a more reliable measure of how well your kidneys are actually filtering your blood.

Could my kidney disease diagnosis be wrong if only creatinine was used?

Possibly. This study found that nearly 17% of patients who appeared to have mild CKD based on creatinine alone actually had normal kidney function when cystatin C was added to the equation. If your estimated GFR is in the 45–59 range based on creatinine, a cystatin C test could clarify your true kidney status.

Read the original research

Estimating glomerular filtration rate from serum creatinine and cystatin C.

The New England journal of medicine, 367(1), 20-9

View on PubMed ↗Publisher’s paper ↗

Citation

Inker, Lesley A; Schmid, Christopher H; Tighiouart, Hocine; Eckfeldt, John H; Feldman, Harold I; Greene, Tom; Kusek, John W; Manzi, Jane; Van Lente, Frederick; Zhang, Yaping Lucy; Coresh, Josef; Levey, Andrew S. (2012). Estimating glomerular filtration rate from serum creatinine and cystatin C.. The New England journal of medicine, 367(1), 20-9. https://doi.org/10.1056/NEJMoa1114248